During inflammatory reactions, endogenously produced cytokines and chemokines act in a network and interact with hormones and neurotransmitters to regulate host immune responses. These signaling circuitries are even more interfaced during infections, when microbial agonists activate TLR, RLR, and NLR receptors. On the basis of the discovery of synergy between chemokines for neutrophil attraction, we extend here this phenomenon between the chemokine MCP-1/CCL2 and the GPCR ligand N-formyl-methionyl-leucyl-phenylalanine or the TLR4 agonist LPS on monocytes. In fact, the bacterial tripeptide fMLP, but not the cytokines IL-1␤ or IFN-␥, significantly and dose-dependently synergized with CCL2 in monocyte chemotaxis. Furthermore, LPS rapidly induced the expression of interleukin-8/CXCL8 but not of the CCL2 receptor CCR2 in monocytic cells. In turn, the induced CXCL8 synergized with CCL2 for mononuclear cell chemotaxis, and the chemotactic effect was mediated by CXCR1/CXCR2, because CXCL8 receptor antagonists or antibodies were capable of blocking the synergy, while keeping the responsiveness to CCL2 intact. These data recapitulate in vitro the complexity of innate immune regulation, provide a novel mechanism of enhancing monocyte chemotaxis during bacterial infections with gram-negative bacteria and demonstrate the importance of local contexts in inflammatory and infectious insults.
Introduction
Upon infection, microbial products [e.g., TLR ligands] and endogenous mediators (e.g., cytokines and chemokines) are sequentially released. In particular, cytokines such as IL-1 and IFNs, induced by viral (e.g., double-stranded RNA) or bacterial (e.g., endotoxins) TLR ligands act in concert as endogenous activators of the immune response, through the induction of chemokines, which function as secondary mediators capable of directly attracting inflammatory cells [1, 2] . In addition to the endogenous chemokines, leukocytes can be attracted by structurally unrelated mediators such as the bacterial peptide fMLP, the lipids leukotriene B4 (LTB4) and PAF. All of these types of leukocyte chemoattractants share the use of seven transmembrane GPCRs to exert their activities [3] . Migrating leukocytes become activated at the site of infection and release secondary messengers that kill microbes (e.g., oxygen radicals) or induce tissue remodeling (e.g., proteases). Cytokines act on leukocytes at multiple levels. They promote leukocyte accumulation in tissues through the induction of chemokines and through the up-regulation and activation of adhesion molecules in response to chemokines [4, 5] . Through cooperation between microbial products and cytokines that are simultaneously produced at the inflammatory focus, as well as the synergistic induction of chemokines by cytokines and TLR ligands, recruited phagocytes rapidly combat infections [2, 6, 7] . The need for more than one stimulus to obtain a strong response provides a control mechanism, allowing maximal leukocyte attraction at the site of inflammation. As an ultimate additional tool of optimal defense against invaders, coproduced chemokines can synergize with each other to enhance the local leukocyte influx [8 -10] .
Priming is a well-described phenomenon in which pre-exposure of leukocytes to TLR ligands or cytokines sensitizes cells to guarantee optimal responses to extracellular inflammatory stimuli, including chemokines [4, [11] [12] [13] [14] [15] . For example, when eosinophils were preincubated with the cytokine IL-5, their chemotactic activity toward eotaxin was enhanced [13, 16] . Recently, we described direct synergy between CC chemokines [e.g., monocyte chemotactic proteins CC chemokine ligand-2 (CCL2) or CCL7] and CXC chemokines (e.g., interleukin-8/ CXCL8 or stromal cell-derived factor-1/CXCL12) to chemoattract neutrophils and monocytes in various in vitro migration assay systems, as well as in vivo [8, 9, 17] . In this study, we investigated the synergistic interaction between structurally unrelated GPCR ligands, i.e., the chemokine CCL2 and the bacterial peptide fMLP, between CCL2 and the cytokines IL-1␤ and IFN-␥, and finally between CCL2 and the TLR ligand lipopolysaccharide (LPS) in monocyte chemotaxis. It is shown that the unrelated GPCR binding inflammatory mediators CCL2 and fMLP cooperate directly, whereas the synergy between the TLR4 ligand LPS and CCL2 might be indirect through fast induction of CXCL8 in the target monocytes.
MATERIALS AND METHODS

Reagents
Natural human CXCL8 and CCL2 were purified to homogeneity from monocyte-derived conditioned medium [18, 19] . The bacterial chemotactic peptide fMLP was purchased from Sigma (St. Louis, MO, USA). LPS from Escherichia coli [0111:B4, partially purified by trichloroacetic acid extraction or highly purified by a modification of the phenol water extraction and pentachlorophenol extraction methods (TLR grade)] were obtained from Sigma or Alexis Biochemicals (Enzo Life Science, NY, USA), respectively. IL-1␤ and IFN-␥ were both purchased from Peprotech (Rocky Hill, NJ, USA). SB225002 was obtained from EMD Chemicals (Gibbstown, NJ, USA). The mouse anti-human CXCR1 (clone 5A12) and CXCR2 antibody (clone 6C6) were purchased from BD PharMingen (Heidelberg, Germany). The purified mouse IgG1 isotype control was obtained from eBioscience (San Diego, CA, USA).
Cells
PBMC were isolated from single blood donations (Blood Transfusion Center of Leuven, Belgium). Erythrocytes were removed by sedimentation for 30 min at 37°C in hydroxyethyl-starch solution (Plasmasteril; Fresenius AG, Bad Homburg, Germany). PBMC and granulocytes were separated by density gradient centrifugation (400 g, 30 min, 15°C) on Ficoll-sodium diatrizoate (Lymphoprep; Invitrogen, Groningen, The Netherlands). Human monocytic THP-1 cells [American Type Culture Collection (ATCC), Manassas, VA, USA] were grown in RPMI 1640 (Cambrex Bio Science, Verviers, Belgium) supplemented with 10% fetal calf serum (FCS; Sigma). LPS-sensitive THP-1 cells (sTHP-1) were slightly more responsive to CXCL8, but not to fMLP.
Chemotaxis
Monocyte migration was measured in the classical Boyden microchamber (Neuro Probe, Cabin John, MD, USA) [17] . Cell fractions and samples were diluted in Hank's balanced salt solution (HBSS; Invitrogen) supplemented with 1 mg/ml human serum albumin (HSA; Belgian Red Cross) and tested in triplicate. The upper wells of the chamber were filled with a PBMC (2ϫ10 6 cells/ml) suspension and separated from the lower wells by a 5-m pore-size polyvinyl pyrrolidone (PVP)-treated polycarbonate membrane (GE Osmonics, Minnetonka, MN, USA). Monocytes were allowed to migrate for 2 h at 37°C. The conditions (cell concentration, use of PVPtreated polycarbonate membrane and 2 h incubation period at 37°C) of the experimental setup were directed to favor monocyte migration. After migration the filters were fixed and stained using Hemacolor solutions (VWR International, Leuven, Belgium). The monocytes that migrated through the pores and adhered to the lower surface of the membrane were counted microscopically (ϫ500 magnification). A chemotactic index (CI) was used to express chemotactic activity and was measured by calculating the number of monocytes migrated to the test sample, divided by the number of monocytes that migrated spontaneously to the dilution buffer. Synergy experiments were performed by adding two different chemoattractants together to the lower wells of the chamber. The multiscreen plate (Millipore Corporation, Billerica, MA, USA) is a disposable device with a 96-well filter plate (5-m pore-size) and a 96-well receiver plate [17] . THP-1 cell migration occurs through the 96-well filter plate in response to a chemotactic gradient. The THP-1 cell suspension (100 l/well in a 96-well filter plate at a concentration of 3.5ϫ10 6 cells/ml) and test samples (150 l/well in a 96-well receiver plate) were diluted in RPMI medium without phenol red and l-glutamine (Cambrex Bio Science) supplemented with 0.1% BSA (endotoxin free, Sigma). After migration (3 h at 37°C), the upper 96-well filter plate was removed and the THP-1 cells in the lower receiver plate were quantified using the luminescence ATP detection assay system (PerkinElmer Life and Analytical Sciences, Boston, MA, USA). The chemotactic activity (CI) was calculated by dividing the luminescence value of the test sample by the luminescence value of the dilution buffer. To study the impact of a CXCR2 antagonist on the synergistic effect, THP-1 cells were treated with SB225002 (10 M) and immediately loaded into the upper wells of the Multiscreen 96-well plate. In receptor neutralization experiments, cells were preincubated with 25 g/ml CXCL8 receptor antibodies or isotype control antibody for 1 h at 37°C before addition of the cells to the test system. Statistically significant differences in chemotactic indices between the combination of two chemoattractants and the sum of the indices obtained for the chemoattractants alone were determined by the MannWhitney U test. For the measurement of CXCL8 in the chemotaxis system, THP-1 cells in the upper wells of the Multiscreen plate were harvested after the 3-h incubation period and centrifuged, and CXCL8 was quantified in the supernatants by ELISA [20] .
Induction experiments
For induction experiments, THP-1 cells and PBMC were seeded in 24-well plates in RPMI supplemented with 2% or 10% FCS, respectively, at a concentration of 1.5 ϫ 10 6 cells/ml or 2.5 ϫ 10 6 cells/ml (1 ml/well) and induced with different doses of LPS (0.005 to 500 g/ml), IL-1␤ (1, 10, or 100 ng/ml) or IFN-␥ (20 or 200 ng/ml) or were left untreated (control). After 2 h (PBMC) or 3 h (THP-1) of induction at 37°C, cell culture-conditioned medium was harvested, clarified (10 min at 1350 g), and kept at -20°C until assay. Levels of human CXCL8 and CCL2 were quantified by specific sandwich ELISAs developed in our laboratory, as described previously [20] .
FACS analysis
THP-1 cells or PBMC were incubated and washed twice with ice-cold FACS buffer (PBS supplemented with 2% FCS). Subsequently, 0.3 ϫ 10 6 cells were labeled with 50 g/ml mouse anti-human FPR monoclonal antibody (clone 5F1; BD PharMingen) or buffer for 30 min on ice. After washing, we incubated the cells with 1.3 g/ml phycoerythrin-conjugated goat antimouse IgG polyclonal antibody (BD PharMingen) for 30 min on ice in the dark. Finally, cells were washed three times with ice-cold FACS buffer, fixed in FACS buffer containing 4% paraformaldehyde, and analyzed using a FACS Calibur flow cytometer (Becton Dickinson, San Jose, CA, USA). Monocytes were gated by their forward-scatter/side-scatter profile. It was previously confirmed that all cells within this gate are CD14 ϩ .
To evaluate the effect of LPS on CCR2 expression by THP-1 cells, the cells (3ϫ10 6 cells/ml) were stimulated during 3 h at 37°C with different concentrations of CCL2, LPS or a combination of CCL2 and LPS diluted in chemotaxis buffer (HBSS ϩ 1 mg/ml HSA). After the incubation period, the cells were washed twice with ice-cold FACS buffer. Subsequently, cells were labeled for 30 min on ice with Alexa Fluor 647 mouse anti-human CCR2 antibody (BD PharMingen) or Alexa Fluor 647 mouse IgG2b isotype control (BD PharMingen).
RESULTS
Synergy between chemokines and other GPCR-binding inflammatory mediators in monocytic cell chemotaxis
To verify whether the bacterial formyl-peptide fMLP directly cooperates with inflammatory chemokines to attract monocytes, fMLP was added together with CCL2 in the Multiscreen chemotaxis system with THP-1 cells. However, different concentrations of fMLP (10 Ϫ11 to 10 Ϫ6 M) were not able to synergize with CCL2 (0.3 to 3 ng/ml) in THP-1 cell chemotaxis in the semiautomated, enzymatic Multiscreen chemotaxis system, but the cellular response to fMLP alone was also absent, most probably due to the lack of its receptor(s) (Fig. 1A, B) . Because we observed that fMLP was able to chemoattract freshly isolated blood monocytes, we confirmed that this cell type expressed the fMLP receptor(s) (Fig. 1A ) [21] . Using the classical Boyden microchamber, we found that fMLP synergized with CCL2 to attract monocytes (Fig. 1C) . Indeed, the combination of fMLP (10 Ϫ10 M) and CCL2 (0.3 ng/ml) caused a statistically significant (i.e., CIϮSE of 27.1Ϯ2.4) increase above the additive monocyte response obtained with CCL2 and fMLP alone (CIϮSE of CI 5.5Ϯ1.1 and 13.7Ϯ1.6, respectively). This indicates that the tripeptide fMLP and the chemokine CCL2, although binding to different GPCRs, can synergize in monocyte chemotaxis.
Lack of synergy between CCL2 and the cytokines IL-1␤ and IFN-␥ in monocyte chemotaxis
Several studies have shown that priming of leukocytes with cytokines enhanced migration to inflammatory chemokines [4, [11] [12] [13] [14] [15] [16] . In a further attempt to study the direct synergy between chemokines and inflammatory cytokines, IL-1␤ or IFN-␥ was combined with CCL2 in the THP-1 Multiscreen chemotaxis system. The cytokines IL-1␤ and IFN-␥ had no direct THP-1 cell chemotactic activity ( Fig. 2A, B) . Moreover, IL-1␤ (1, 10, and 100 ng/ml) ( Fig. 2A) nor IFN-␥ (20 and 200 ng/ ml) ( Fig. 2B ) were able to synergize with CCL2 (0.3, 1, and 3 ng/ml), despite the fact that IFN-␥ and IL-1␤ induce receptormediated events in THP-1 cells [22, 23] . Similarly, IL-1␤ (1, 10, and 100 ng/ml) (Fig. 2C) or IFN-␥ (20 and 200 ng/ml) ( Fig. 2D) were not able to increase the chemotactic activity of CCL2 (1, 3, and 10 ng/ml) for freshly isolated monocytes in the Boyden microchamber assay.
Synergy between LPS and CCL2 in monocytic cell chemotaxis
It has previously been described that the chemotactic effect of CCL2 on freshly isolated peripheral blood monocytes was significantly enhanced in the presence of the CXC chemokines CXCL8 and CXCL12 using the Boyden microchamber assay .3, 1, and 3 ng/ml) were combined with multiple concentrations of the GPCR ligand fMLP (10 Ϫ11 to 10 Ϫ6 M) in the lower compartment of the enzymatic multiscreen chemotaxis assay to measure THP-1 cell chemotaxis (B) or in the lower compartment of the Boyden microchamber to measure monocyte migration (C). The conditions were set (see Materials and Methods) to selectively measure monocyte chemotaxis. The chemotactic response is expressed as the mean chemotactic index (CI), derived from 3 to 10 independent experiments. The se did not exceed 30% of the mean chemotactic index. Statistically significant differences in chemotactic indices between the combination of CCL2 and fMLP and the sum of the indices obtained for the chemoattractants alone, determined by the Mann-Whitney U test, are indicated by an asterisk (*, PϽ0.05). [17] . For comparison, different concentrations of the CXCR2 agonist CXCL8 (0.3, 1, 3, 10, 30, and 300 ng/ml) were directly (simultaneously added) combined together with suboptimal concentrations of CCL2 (0.3, 1, and 3 ng/ml) in the Multiscreen chemotaxis assay using monocytic THP-1 cells. Figure 3A shows a dose-dependent synergistic interaction between the CC and CXC chemokine. For example, CXCL8 at a suboptimal concentration of 3 ng/ml (CIϮSE of 2.7Ϯ0.5) was able to significantly increase (Pϭ0.019, CIϮSE of 6.7Ϯ0.9) the chemotactic response of THP-1 cells, expressing CXCR2, toward a rather inactive concentration of CCL2 of 0.3 ng/ml (CIϮSE of 2.4Ϯ0.3) (Fig. 3A) . At higher concentrations of CXCL8 (CIϮSE of 4.5Ϯ1.6 at 30 ng/ml) and CCL2 (CIϮSE of 10.4Ϯ1.4 at 3 ng/ml), the combined effect was rather additive (CIϮSE of 13.0Ϯ2.2). Moreover, the chemotactic response of LPS-sensitive THP-1 cells (sTHP-1 are also more sensitive to CXCL8) toward suboptimal concentrations of CCL2 (1 and 3 ng/ml) was enhanced in the presence of a lower rather inactive concentration of CXCL8 (1 ng/ml) (Fig. 3B) . It can be deduced that the optimum of synergy between two chemokines is influenced by the sensitivity of the target cells.
Next, the TLR4 ligand LPS, a pattern recognition molecule that initiates innate immune responses, was investigated. The CC chemokine CCL2 (0.3, 1, and 3 ng/ml) in combination with different concentrations of LPS (0.005 to 500 g/ml) was tested on THP-1 and LPS-sensitive sTHP-1 cells. Figure 4 , A and B show that simultaneous addition of a suboptimal concentration of CCL2 (1 ng/ml) and 50 g/ml (for THP-1 cells) or 50 ng/ml (for sTHP-1 cells) of LPS resulted in a statistically significant increase in cell migration. We deduced that the sTHP-1 cells are 1000 times more sensitive to LPS compared with the THP-1 cells and hence provide synergy with CCL2 at a much lower concentration (Fig. 4, A and B) . Moreover, to exclude that the synergy between CCL2 and LPS is due to the presence of contaminating lipids in the LPS preparation, we tested LPS of high purity (Alexis Biochemicals, TLRgrade). Such pure LPS at a concentration of 50 and 500 ng/ml was also able to significantly increase the chemotactic activity of CCL2 (3 ng/ml) for sTHP-1 cells (Fig. 4C) . Finally, in a more physiological context, highly purified LPS at 500 ng/ml increased the chemotactic activity of CCL2 for freshly isolated monocytes when the chemokine was applied at a suboptimal concentration (1 ng/ml) (Fig. 4D) .
LPS does not influence CCR2 expression on THP-1 cells
In the next experimental setting, we examined whether the enhancing effect of LPS on CCL2-induced monocytic migration might be mediated by an up-regulation of CCR2 expression. THP-1 cells were incubated with different concentrations of LPS (0.5 to 500 g/ml) alone or in combination with CCL2 (0.3, 1, and 3 ng/ml) for the duration of the chemotaxis assay (3 h), and CCR2 expression was subsequently compared using FACS analysis. We did not find any changes in the expression of CCR2 after 3 h of stimulation by LPS or by the combination of LPS with low but synergizing concentrations of CCL2 (Ͻ3 ng/ml) (Fig. 5) . Thus, the synergy between LPS and CCL2 in THP-1 cell chemotaxis cannot be explained by fast up-regulation of CCR2 expression at the cell surface. As a control, CCR2 was significantly down-regulated by high concentrations of CCL2 (1 g/ml), using the same experimental conditions (Fig. 5) .
Rapid induction of CXCL8 in monocytic cells by LPS is responsible for its synergy with CCL2
Because LPS is a potent inducer of chemokines and was cooperating with CCL2, we wondered whether the synergy between CCL2 and LPS in monocyte chemotaxis was due to an indirect effect during the assay. To that goal THP-1 and sTHP-1 cells were stimulated with different concentrations of LPS (0.005 to 500 g/ml) for only 3 h, the time period during which the THP-1 cells were allowed to migrate. Figure 6A , B shows that dependent on the dose and cell line, LPS induced low but significant CXCL8 production (up to 10 ng/ml). These amounts of CXCL8 are able to synergize with CCL2 in THP-1 and sTHP-1 cell chemotaxis (see also Fig. 4A, B) . Thus, the synergy between LPS and CCL2 in THP-1 cell chemotaxis can at least, in part, be explained by the synergy between CCL2 and rapidly induced CXCL8.
Similarly, PBMC also significantly produced CXCL8 (within 2 h of stimulation with LPS) at sufficient levels to explain indirect cooperation with CCL2 to generate synergy for monocyte chemotaxis in an autocrine fashion (Figs. 6C and 4D ). In contrast to CXCL8, CCL2 production by PBMC was not significantly enhanced after 2 h of stimulation with different concentrations of LPS.
To further demonstrate that LPS synergizes with CCL2 in monocyte chemotaxis via induction of CXCL8, we measured the direct release of CXCL8 in the migration assay environment. CCL2 was either added alone or combined with LPS in the lower compartment of the Multiscreen chemotaxis system. After 3 h of sTHP-1 migration, the production of CXCL8 in the upper compartment was measured. Table 1 shows that CXCL8 was not detected in the supernatants of sTHP-1 cells after stimulation with CCL2 alone. In contrast, CXCL8 was produced in response to LPS alone or a combination of LPS and CCL2. Thus, the produced CXCL8 can cooperate with CCL2 in THP-1 cell chemotaxis in an autocrine fashion ( Table 1) .
The lack of synergy between CCL2 and IL-1␤ or between CCL2 and IFN-␥ in monocyte chemotaxis (Fig. 2) is concordant with the absence of CXCL8 production in response to IL-1␤ (10 and 100 U/ml) or IFN-␥ (20 and 200 ng/ml) within 2 or 3 h of stimulation of the PBMC or THP-1 cells, respectively (Fig. 6 ).
The synergistic interaction between CCL2 and the TLR ligand LPS in monocyte chemotaxis is inhibited by CXCL8 receptor antagonists or antibodies
To further demonstrate that the synergy between CCL2 and LPS in monocyte chemotaxis implies the induction of CXCL8 by LPS, the combination of CCL2 (1 ng/ml) and LPS (50 ng/ ml) was evaluated in the Multiscreen chemotaxis assay with sTHP-1 cells in the presence of the CXCR2 specific antagonist SB225002 (10 M) (Fig. 7A) . SB225002 did not influence the chemotactic activity of CCL2 alone, but it significantly reduced (Pϭ0.036) the synergistic effect between CCL2 and LPS observed in the absence of SB225002 (Fig. 7A) . Alternatively, the CXCL8-mediated synergy between CCL2 and LPS was confirmed with the use of antibodies against the CXCL8 receptors. Therefore, THP-1 cells, expressing CXCR2 [17] , were preincubated with anti-CXCR2 before addition of the cells to the upper compartment of the test system (Fig. 7B) . It was observed that the synergistic effect between LPS and CCL2 were significantly inhibited by anti-CXCR2 (25 g/ml). Finally, we CXCL8 (0.3 to 300 ng/ml) was combined with different concentrations of CCL2 (0.3, 1, and 3 ng/ml) in the lower compartment of the enzymatic multiscreen chemotaxis assay to measure THP-1 (A) or LPSsensitive THP-1 (sTHP-1; B) cell chemotaxis. The chemotactic response is expressed as the mean CI, derived from 3 to 10 independent experiments. The se did not exceed 30% of the mean chemotactic index. Statistically significant differences in chemotactic indices between the combination of CCL2 and CXCL8 and the sum of the indices obtained for the chemoattractants alone, determined by the MannWhitney U test, are indicated by asterisks (*, PϽ0.05).
evaluated the synergy between CCL2 (5 ng/ml) and LPS (500 ng/ml) observed with monocytes, which expressed both CXCR1 and CXCR2 (Fig. 7C) [17] . After preincubation of the PBMCs with a combination of 25 g/ml of anti-CXCR1 plus 25 g/ml anti-CXCR2 antibody, loss of synergy between CCL2 and LPS was noticed. In contrast, in the absence of the anti-CXCR1 plus anti-CXCR2 antibody, LPS (500 ng/ml) was able to significantly (P ϭ 0.049) enhance the chemotactic activity of CCL2 (5 ng/ml) for monocytes. Moreover, preincubation of the PBMCs with a combination of the anti-CXCR1 plus anti-CXCR2 antibody did not influence the chemotactic activity of CCL2 alone. The isotype control antibody did not influence the synergy between LPS and CCL2 (data not shown). We can conclude that the synergy between CCL2 and LPS in monocyte chemotaxis is, like in THP-1 cells, due to the synergy between CCL2 and CXCL8, produced by the monocytes upon stimulation with LPS.
DISCUSSION
Monocytes are a population of mononuclear leukocytes that develop in the bone marrow and traffic into tissues under normal conditions to replenish resident macrophages and dendritic cells. Moreover, in response to chemotactic factors, monocytes can move quickly to sites of infection and contribute to inflammatory and immune responses [24] . Monocytes transgress the vascular endothelium and migrate into the underlying tissue in response to a gradient of chemotactic cytokines, which stimulate migration by activating GPCR and subsequent downstream signaling pathways [25, 26] . Recent research has focused on the mechanisms underlying chemotaxis of monocytes into tissues and inflammatory sites [27, 28] . Classically, monocytes are recruited by endogenous monocyte chemotactic proteins (MCPs). In the human species, CCL2 is the most abundant MCP that binds to a single receptor, CCR2.
The leukocyte infiltrate during immune responses depends on the balance of antagonistic or synergistic interactions between the many mediators (i.e., TLR ligands, cytokines) present in the complex inflammatory environment and on the chemoattractant concentration and the time period during which chemotactic gradients remain established.
Recently, we found that the CXC chemokines CXCL12 and CXCL8 dose-dependently increased the migration of monocytes toward suboptimal concentrations of CCL2 [17] . Here, we focused on the possible synergistic interactions of TLR ligands and cytokines with chemokines as an additional mechanism to further increase monocyte recruitment to sites of infection. In contrast to the synergy between CXC and CC chemokines, the combination of the structurally unrelated GPCR ligands, i.e., bacterial tripeptide fMLP and CCL2 did not provide synergy in THP-1 cell chemotaxis. However, fMLP was able to cooperate with CCL2 to attract peripheral blood monocytes in the Boyden chamber assay. These apparently contradictory data corroborate our previous findings that, to 3, 1 , and 3 ng/ml) were combined with multiple concentrations of LPS (0.005 to 500 g/ml, Sigma) in the lower compartment of the enzymatic multiscreen chemotaxis assay to measure THP-1 (A) or LPS-sensitive THP-1 (sTHP-1; B) cell chemotaxis. (C) Different concentrations of CCL2 (0.3, 1, and 3 ng/ml) were combined with multiple concentrations of highly purified LPS (0.005 to 5 g/ml; Alexis Biochemicals) in the lower compartment of the enzymatic multiscreen chemotaxis assay to measure sTHP-1 cell chemotaxis. (D) CCL2 (1, 3 , or 10 ng/ml) was combined with different concentrations of LPS (50, 500, or 5000 ng/ml; Alexis Biochemicals) in the lower compartment of the Boyden microchamber to measure monocyte chemotaxis. The chemotactic response is expressed as the mean CI, derived from 3 to 7 independent experiments. The se did not exceed 30% of the mean chemotactic index. Statistically significant differences in chemotactic indices between the combination of CCL2 and LPS and the sum of the indices obtained for the chemokine and LPS alone, determined by the Mann-Whitney U test, are indicated by asterisks (*, PϽ0.05).
obtain leukocyte synergy, binding and signaling of the two chemoattractants to their proper receptor is necessary [8, 17] . Indeed, fMLP alone was able to significantly chemoattract monocytes, indicating that this bacterial tripeptide functionally recognizes the fMLP receptor expressed on monocytes. In contrast to monocytes, fMLP alone did not induce chemotactic responses in THP-1 cells. In our study, THP-1 cells lack surface expression of the fMLP receptor FPR, although other authors have detected FPR expression in THP-1 cells after permeabilization of the cell membrane [29] . These data show that besides the synergy between two chemokines to attract monocytes, chemokines can also cooperate with GPCR ligands (i.e., fMLP) through receptor-mediated events. Previous studies from our laboratory have shown that the chemotactic effect of fMLP on neutrophils was significantly enhanced in the presence of the CC chemokine regakine-1 [30] . Furthermore, the chemoattractant PAF, a potent proinflammatory phospholipid messenger and agonist of the PAF receptor (another GPCR), was able to enhance monocyte chemotaxis induced by CCL2 [31] . Further, the GPCR ligand histamine, a major mediator of allergic reactions, interacts with CXCL12 to promote human mast cell migration [32] . When the histamine receptor (H 4 receptor) was blocked by selective antagonists in this migration assay, the effect of histamine disappeared. Klein et al. demonstrated that eotaxin and LTB 4 , a lipid chemoattractant and GPCR agonist, cooperated to induce eosinophil recruitment during an allergic inflammatory response in mice [33] . All of these data indicate that synergy in leukocyte recruitment occurs via GPCR binding and signaling.
Cytokines such as IL-1␤ and IFN-␥ synergistically induce chemokine production, which may, in turn, cooperate to chemoattract leukocytes [2, 7] . The potential direct interaction between chemokines and cytokines may also be important for the accumulation and activation of leukocytes at the site of inflammation [34] . However, IL-1␤ or IFN-␥ were not able to synergize with CCL2 in monocyte chemotaxis. Hu et al. (2005) demonstrated that priming of macrophages with IFN-␥ (preincubation with IFN-␥ for 48 h before migration toward CCL2 was evaluated) exhibited increased migration in response to CCL2 due to up-regulation of GPCR expression [15] . In our case, IFN-␥ was added simultaneously with CCL2 in the lower compartment of the chemotaxis system to allow direct cooperation at the level of signal transduction. This difference in experimental setup might clarify the discrepancy between the data. Hu et al. (2008) found that IFN-␥ rather inhibited monocyte migration in response to CCL2 when added simultaneously to the test cells [35] .
The Toll-like receptor (TLR) family comprises an extremely important series of recognition receptors of the innate immune system, to provide detection of microbial infection and to link innate and adaptive immunity. TLR ligands (e.g., LPS) are present together with chemokines at the site of infection. LPS was found to regulate cell trafficking by indirect mechanisms such as regulation of chemokine receptor expression or chemokine production or changes in signaling through GPCRs [36 -44] . In this study, we described the synergy between CCL2 and the TLR4 ligand LPS in monocyte migration, although LPS had no effect on CCR2 cell surface expression within the time frame of the assay. The data show that LPS rather rapidly induces CXCL8 release by the responder monocytic cells. Our data are not in contradiction with the results of Sica et al. [39] , who demonstrated that LPS-induced inhibition of CCR2 mRNA expression was associated with a reduction of both CCL2 binding and chemotactic responsiveness. These authors preincubated the monocytes for 4 h with low LPS concentrations before measuring CCR2 mRNA expression [39] . In our case, CCL2 and LPS were added simultaneously to the lower compartment of the chemotaxis system. We showed that the synergy between LPS and CCL2 in monocyte chemotaxis can at least, in part, be explained by an indirect effect, namely the synergy between CCL2 and CXCL8, produced by these cells after stimulation with LPS. Indeed, LPS dose-dependently induced low but significant CXCL8 production, sufficient to (1 ng/ml), LPS (50 ng/ml, Sigma), and CCL2 (1 ng/ml) plus LPS (50 ng/ml) were added to the lower compartment of the multiscreen chemotaxis assay to measure sTHP-1 cell chemotaxis. Cells were treated with SB225002 (10 M) or buffer and immediately loaded into the upper wells of the multiscreen plate. The chemotactic response is expressed as the mean CI, derived from 3 independent experiments. (B) CCL2 (3 ng/ml), LPS (5 g/ ml, Sigma), and CCL2 (3 ng/ml) plus LPS (5 g/ml) were added to the lower compartment of the multiscreen chemotaxis assay to measure THP-1 cell chemotaxis. Cells were preincubated (1 h, 37°C) with CXCR2 antibody (25 g/ml) or buffer before loading in the upper compartment of the multiscreen plate. The chemotactic response is expressed as the mean CI, derived from 6 independent experiments. (C) CCL2 (5 ng/ml), highly purified LPS (500 ng/ml, Alexis Biochemicals) and CCL2 (5 ng/ml) plus LPS (500 ng/ml) were added to the lower compartment of the Boyden chamber to measure monocyte chemotaxis. PBMCs were preincubated (1 h, 37°C) with 25 g/ml CXCR1 plus 25 g/ml CXCR2 antibody or buffer before loading in the upper compartment of the Boyden chamber. The chemotactic response is expressed as the mean CI, derived from 3 independent experiments. The statistically significant reduction in synergy between LPS and CCL2 in the presence of CXCL8 receptor antagonist or antibodies is determined by the Mann-Whitney U test on paired values and is indicated by an asterisk (*, PϽ0.05).
synergize in an autocrine manner with CCL2 in monocyte chemotaxis. Furthermore, the synergy between LPS and CCL2 in monocyte chemotaxis was reduced by (pre-)incubation of the cells with CXCL8 receptor antagonists or antibodies. However, unlike LPS, IL-1␤, and IFN-␥ failed to rapidly induce CXCL8, excluding both a direct (signal transduction) or indirect (induction of synergizing chemokine) effect to synergize with CCL2 in monocyte attraction. Taken together, this indicates that in an early stage of infection, LPS and CCL2 can synergize, whereas this effect can be counteracted at a later stage through inhibition of CCR2 expression by LPS.
From our in vitro data, it can be deduced that the phenomenon of synergy between chemokines and other GPCR ligands or TLR ligands is a matter of multiple parameters. These include 1) time (direct chemokine effect vs. indirect TLR effect via chemokine induction), 2) place (chemokines develop a different gradient in vivo and some may be quickly processed by NH 2 -terminal cleavage depending on the presence of proteases, e.g., CD26 and MMPs), 3) chemokine dose and sensitivity of the cells (for each combination a different optimal and narrow in vitro concentration range is required for each ligand, which also depends on the cell type). Indeed, we found different patterns of synergistic responses at comparing monocytes and THP-1 cells, whether LPS-sensitive or not. Furthermore, natural CCL2 may be glycosylated in vivo, which will affect its pharmacokinetics. As a consequence, the evaluation of monocyte infiltration in vivo is much more difficult, since all these parameters need to be optimal to generate measurable synergistic interactions between chemokines and chemokine inducers.
In conclusion, the enhancement of the inflammatory response by synergistic interactions of immune modulators is complex. TLR ligands induce cytokines which, in turn, synergize to produce chemokines but also directly provide autocrine chemokines which cooperate with paracrine chemokines to enhance inflammation.
